Price Action Don’t Lie: Could Aralez Pharmaceuticals Inc Change Direction After Today’s Significant Increase?

Price Action Don't Lie: Could Aralez Pharmaceuticals Inc Change Direction After Today's Significant Increase?

The stock of Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) is a huge mover today! About 521,067 shares traded hands or 3.89% up from the average. Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) has risen 9.37% since April 26, 2016 and is uptrending. It has outperformed by 4.11% the S&P500.
The move comes after 7 months positive chart setup for the $305.54M company. It was reported on Nov, 29 by We have $5.44 PT which if reached, will make NASDAQ:ARLZ worth $27.50M more.

Analysts await Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) to report earnings on March, 21. They expect $-0.34 earnings per share, up 15.00% or $0.06 from last year’s $-0.4 per share. After $-0.32 actual earnings per share reported by Aralez Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 6.25% negative EPS growth.

According to Zacks Investment Research, “Aralez Pharmaceuticals Inc. is a global specialty pharmaceutical company. They acquire, develop and commercialize products primarily in cardiovascular, pain and other specialty areas.”

More notable recent Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) news were published by: which released: “Aralez: Zigging When The Pharma Industry Is Zagging” on November 28, 2016, also with their article: “Aralez Pharmaceuticals Inc (ARLZ) Soars on AstraZeneca Deal” published on October 04, 2016, published: “Why Aralez Pharmaceuticals Inc Jumped Higher Today” on August 01, 2016. More interesting news about Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) were released by: and their article: “Plus the latest data from on 21 home markets across the US” published on February 12, 2016 as well as‘s news article titled: “Why Aralez Pharmaceuticals Inc. Approved a Higher Price Today” with publication date: September 15, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment